Melatonin MT 2 receptor is expressed and potentiates contraction in human airway smooth muscle
Sasaki H., Zhang Y., Emala CW., Mizuta K.
Prospective Study, published in Am J Physiol Lung Cell Mol Physiol (2021) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- Am J Physiol Lung Cell Mol Physiol (2021)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 34612067
- PMCID
- PMC8715028
- DOI
- 10.1152/ajplung.00273.2021
- Citations
- 7
Abstract (original English)
Nocturnal asthma is characterized by heightened bronchial reactivity at night, and plasma melatonin concentrations are higher in patients with nocturnal asthma symptoms. Numerous physiological effects of melatonin are mediated via its specific G protein-coupled receptors (GPCRs) named the MT 1 receptor, which couples to both G q and G i proteins, and the MT 2 receptor, which couples to G i . We investigated whether melatonin receptors are expressed on airway smooth muscle; whether they regulate intracellular cyclic AMP (cAMP) and calcium concentrations ([Ca 2+ ] i ), which modulate airway smooth muscle tone; and whether they promote airway smooth muscle cell proliferation. We detected the mRNA and protein expression of the melatonin MT 2 but not the MT 1 receptor in native human and guinea pig airway smooth muscle and cultured human airway smooth muscle (HASM) cells by RT-PCR, immunoblotting, and immunohistochemistry. Activation of melatonin MT 2 receptors with either pharmacological concentrations of melatonin (10-100 µM) or the nonselective MT 1 /MT 2 agonist ramelteon (10 µM) significantly inhibited forskolin-stimulated cAMP accumulation in HASM cells, which was reversed by the Gα i protein inhibitor pertussis toxin or knockdown of the MT 2 receptor by its specific siRNA. Although melatonin by itself did not induce an initial [Ca 2+ ] i increase and airway contraction, melat
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.